2022 American Transplant Congress
Induction Immunosuppression in ABO-Incompatible Liver Transplant Recipients
1Keck Medicine of USC, Los Angeles, CA, 2Keck School of Medicine, Los Angeles, CA
*Purpose: ABO-incompatible (ABO-i) liver transplantation (LT) has been associated with an increased risk of AMR, as well as poor patient and graft survival. With advances…2022 American Transplant Congress
Brief Human IL-2 Mutein Therapy Induces Foxp3+ T-Regulatory Cell Expansion and Donor-Specific Allograft Tolerance
*Purpose: New therapeutic approaches to the management of transplant recipients are warranted in efforts to improve outcomes.*Methods: We have engineered a modified human IL-2 protein…2022 American Transplant Congress
Standard Induction with Basiliximab versus no Induction in Low Immunological Risk Kidney Transplant Recipients: Study Protocol for a Randomized Controlled Trial
1KFSHRC, RIYADH, Saudi Arabia, 2MOH, RIYADH, Saudi Arabia
*Purpose: To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC…2022 American Transplant Congress
A Novel IL-2 Mutein Selectively Expands Regulatory T Cells and Prolongs Skin Graft Survival
*Purpose: Promoting immune regulation through expansion of regulatory T cell (Treg) may allow immunosuppression minimization and improve long-term graft outcomes. Low-dose IL-2 is known to…2021 American Transplant Congress
Selective Regulatory T Cell Expansion by a Novel IL-2 Mutein Prolongs Skin Transplant Survival in Mice
*Purpose: Long-term immunosuppression predisposes transplant patients to a greater risk of infection, malignancy and kidney toxicity. Hence, alternative methods to regulate the immune system are…2021 American Transplant Congress
Outcomes of Cytomegalovirus Status Determining Induction Therapy in Lung Transplant
*Purpose: At the study institution, basiliximab induction is withheld in lung transplant recipients who are cytomegalovirus (CMV) high risk due to concern for increased CMV…2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…2019 American Transplant Congress
PD-1+CD3+CD4-CD8- (Double Negative T-cells) Are Early Responders during Kidney Ischemia Reperfusion Injury and Regulated by Non-Classical MHC Molecules
Johns Hopkins University and School of Medicine, Baltimore, MD
*Purpose: Unconventional T-cells (e.g. Tregs and γδT-cells) are increasingly recognized for their roles in maintaining homeostasis and protecting non-lymphoid tissues against injury/stress. Double negative (DN)…2019 American Transplant Congress
To Each Their Own: Center-Level Variation in Tailoring Induction Immunosuppression to Kidney Transplant Recipients
Johns Hopkins University, Baltimore, MD
*Purpose: Ideally, induction immunosuppression should be selected in a personalized manner. However, there is little knowledge of what clinical factors are considered in this process…2019 American Transplant Congress
Lymphotoxin Signaling Regulates T Cell Lymphatic Trafficking
*Purpose: Lymphotoxin (LT) α1β2 is crucial for lymphatic organ development and orchestration of immune responses. LTα1β2 is preferentially expressed by regulatory T cells (Treg) for…
American Transplant Congress abstracts